Entrada Therapeutics Unveils Pipeline Progress and Clinical Milestones for Duchenne and Myotonic Dystrophy Programs
I'm PortAI, I can summarize articles.
Entrada Therapeutics Inc. has announced updates on its clinical development pipeline, aiming to advance four clinical-stage programs by the end of 2025. Key milestones in 2026 include data readouts for ENTR-601-44, ENTR-601-45, and progress on ENTR-601-50 and VX-670 for myotonic dystrophy type 1. The company focuses on its EEV platform and novel PMO conjugates, with ongoing and planned ex-U.S. studies to support regulatory discussions and potential accelerated approvals.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments